Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7 trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2/3

NCT01810913

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in…

United States613 participantsStarted 2013-03-22

Treatment: Atezolizumab, Biopsy Procedure

All recent trials (5 shown)

Active — Not RecruitingPhase 2

NCT03468218

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to…

United States36 participantsStarted 2018-09-18

Treatment: Cabozantinib, Pembrolizumab

TerminatedPhase 2

NCT02917629

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx canc…

United States6 participantsStarted 2018-05-31

Treatment: Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

All recent trials (5 shown)

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiat…

All recent trials (5 shown)

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer